Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Valerina Changarathil

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

November 15, 2024
Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.
Read Transcript

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Ellerston Capital portfolio manager Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Speaking at the Sohn Australia conference in Adelaide on Friday, Mr Kourtis lifted the entertainment quotient with his inimitable presentation style, all while donning a doctor’s white coat.

The well known avowed contrarian investor, with over 40 years experience, last year picked then unloved stock ResMed, which has gained more than 60 per cent in the last 12 months to currently trade close to $36 on the ASX.

Ellerston Capital, headquartered in Sydney, has over $5bn invested in traditional and alternative assets and Mr Kourtis told the conference his fund’s single biggest position is in Perpetual.

“The patient I’m diagnosing today, is suffering from a severe case of shareholder wealth destruction – it’s Perpetual!” he said at the conference, which raises money for medical research.

“Perpetual is at a 20-year low. It wasn’t that long ago the stock was at $80. The problem has been very poor leadership at the very top, poor capital allocation and woeful execution.”

Recent deals, including the $2bn acquisition of rival fund manager Pendal that was completed in early 2023 left the asset manager saddled with debt.

Perpetual in May inked a deal with private equity giant KKR to sell its wealth and corporate trust divisions, along with the 138-year-old Perpetual name, in a deal still to be voted on by shareholders.

Last month, Perpetual received a first strike against its executive pay, with Mr Kourtis saying “we’re not going to reward for poor execution”.

Perpetual is now working through a $2.2bn deal with global equity giant KKR. Perpetual will sell its name, along with its prized wealth management business to KKR and focus on a streamlined asset management function.

Perpetual’s corporate trust business will also be part of the KKR deal, with proceeds being used to pay off debt for the group which was worth $771m as of the end of April and the rest returned to shareholders.

“There’ll be some debt repaid, separation costs, net adjustments – but at the end of the day, shareholders are going to receive about a billion dollars,” Mr Kourtis said.

“What does that leave us with? A high quality operating platform, $222bn assets under management, we all know the brands. Importantly 70 per cent of their funds under management, is about to overperform the benchmark.”

He said Perpetual’s problem was its “empire building” likening its Pitt Street office in Sydney to “the Taj Mahal, fit for a Saudi prince”.

“That’s going to get sorted out.”

“It will be the cheapest listed asset manager of scale in the universe … The implied enterprise value of Residual Co is going to be under 4x EBITDA. That is cheap!”

He is backing new chief executive Bernard Reilly, who is prioritising fixing its operating model and cost base.

“Bernie understands cost-cutting and if they can’t take 10 per cent out of that cost base … I’ll give up my doctorship”, he said

Mr Kourtis said “lots could go wrong” with his bet, including issues with the approvals or the tax relief ruling despite his “serious regression analysis”.

But investors would still be “back to the future” with a “pretty decent fund manager”.

“You are basically getting a fund manager for nothing.”

75 per cent of their strategies have outperformed over a three-year period and is good track record, he said.

“The problem hasn’t been performance. It has been with the board, the ex-CEO (Rob Adams) and the execution strategy”.

He said his tip came with an important disclaimer – “we accept no liability for nothing”.

“It really is a gift”, he said, revealing he is “long 10 per cent higher”.

“I am giving you all a fighting headstart”.

Perpetual shares are up nearly 3 per cent to $20.98 in current trading.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts
October 3, 2023

Understanding the 4 pillar framework underpinning a high conviction strategy

Listen to episode one with Chief Investment Officer Charlie Lanchester and TDM Growth Partners Investment Team Members Ed Cowan and Fraser Christie. They share their unique investment philosophies and delve into two high conviction stocks recommended for the HM1 portfolio.

Read More
investing

No results found.

Please try a different search keyword or filter.